Friends & Family

“"I know from personal experience...getting anxious kids help early can be crucial in heading off more serious problems later in life."”

A Childhood Darkened by Severe Anxiety Becomes Brighter

Childhood anxiety, even severe and chronic, doesn’t necessarily stand in the way of success and achievement. But caring parents will do anything to help relieve their children of misery. Scott Stossel, the editor of The Atlantic magazine, tells his story of struggling, coping, and living a very productive life.

Read

Suicide

Robin WilliamsADAA mourns the loss of Robin Williams and others whose lives have ended due to suicide. His tragic death illustrates the great need for increased public awareness of the grave risk that suicide poses.

Cognitive-Behavioral Therapy vs. Supportive Psychotherapy for Adults With Body Dysmorphic Disorder (BDD)

The purpose of this study is to learn which of two forms of therapy is more likely to help people who have body dysmorphic disorder (BDD). We are comparing cognitive-behavioral therapy (CBT), which is a promising new treatment for BDD, and supportive psychotherapy (SPT), which appears to be the most widely used therapy in the community to treat BDD and related problems, such as low self-esteem or problems with family members or friends.

Study Treatments

Organization: 
Brown University, Rhode Island Hospital
Principal Investigator: 
Katharine Phillips, MD
Eligibility Criteria: 

Adults (age18 or older):

  • Have BDD.
  • Live within driving distance of Boston, Massachusetts.
  • Meet further qualifications for this study.
Contact: 
Phone: 877-4MGH-BDD or email BDD@Lifespan.org
Location: 
Massachusetts General Hospital
State: 
Massachusetts
Study End Date: 
Sat, 2016-04-30

Integrated PTSD and Smoking Treatment

Research shows that people with PTSD are more likely to smoke than people without PTSD. It also shows that people with PTSD have more difficulty at attempts to quit smoking. This study is part of a program aimed at finding out how best to help smokers quit who also have PTSD.

Organization: 
The University of Texas at Austin
Principal Investigator: 
Mark B. Powers, PhD
Eligibility Criteria: 
  • Male and female patients ages 18 to 65 capable of providing informed consent
  • Willing and able to provide informed consent, attend all study visits and comply with the protocol
  •  Daily smoker for at least 3 months
  • Currently smoke an average of at least 8 cigarettes per day
  • Report a motivation to quit smoking in the next month of at least 5 on a 10-point scale
  • Meet criteria for current diagnosis of PTSD via structured clinical interview
Exclusion Criteria: 
  • Current diagnosis of a psychotic, eating, developmental, or bipolar disorder
  • Significant suicide risk as determined by structured interview
  • Psychoactive substance abuse or dependence (excluding nicotine dependence) within the past 6 months
  • Limited mental competency and the inability to give informed, voluntary, written consent to participate
  • Current use of any pharmacotherapy or psychotherapy for smoking cessation not provided by the researchers during the quit attempt
  • Current psychotherapy directed specifically toward treatment of PTSD
  • Use of other tobacco products
  • Planning on moving (outside of the immediate area) in the next 6 months
  • Insufficient command of the English language (i.e., cannot carry on a conversation with an interviewer in English or read associated text)

 

Contact: 
Brooke Kauffman, 512-471-1117; treatment@utexas.edu
Location: 
The University of Texas at Austin
State: 
Texas
Study End Date: 
Sat, 2018-06-30

Enhancing Panic and Smoking Reduction with D-Cycloserine

The purpose of the current study is to evaluate the efficacy of d-cycloserine in augmenting treatment of smoking cessation for individuals with panic attacks. Individuals will receive 7 weeks of panic- and smoking-reduction treatment (PSRT) and one pill of d-cycloserine (DCS) or one pill placebo one hour prior to sessions 3, 4, and 5 (i.e., 3 single doses). Participants will also be given nicotine replacement therapy as part of PSRT (i.e., the patch).

Principal Investigator: 
Jasper Smits, PhD
Eligibility Criteria: 
  • Male and female patients ages 18 to 65 capable of providing informed consent
  • Willing and able to provide informed consent, attend all study visits and comply with the protocol
  • Daily smoker for at least one year
  • Currently smoke an average of at least 10 cigarettes per day
  • Report a motivation to quit smoking in the next month of at least 5 on a 10-point scale
  • Evidence of panic attack within the past year and endorsement of smoking as an emotion regulation strategy (i.e., score at least a 78 on the SAEQ).
Exclusion Criteria: 
  • Subjects who do not use smoking as an emotion-regulation strategy 
  • Current diagnosis of a psychotic, eating, developmental, or bipolar disorder
  • Significant suicide risk as determined by structured interview
  • Pregnant women, lactating women, and women of childbearing potential who are not using medically accepted forms of contraception (e.g., IUD, oral contraceptives, barrier devices, condoms and foam, or implanted progesterone rods stabilized for at least 3 months)  
  • Psychoactive substance abuse or dependence (excluding nicotine dependence) within the past 6 months
  • Current use of isoniazid or ethionamide compounds
  • A history of significant medical condition and/or be deemed as currently unhealthy in the context of a complete physical examination
  • Limited mental competency and the inability to give informed, voluntary, written consent to participate
  • Current use of any pharmacotherapy or psychotherapy for smoking cessation not provided by the researchers during the quit attempt
  • Concurrent psychotherapy initiated within three months of baseline, or ongoing psychotherapy of any duration directed specifically toward treatment of anxiety or mood disorder other than general supportive therapy initiated at least 3 months prior to the study
  • Use of other tobacco products
  • Plans to move outside of the immediate area in the next 6 months
  • Insufficient command of the English language

 

Contact: 
Brooke Kauffman, 512-471-1117; treatment@utexas.edu
Location: 
The University of Texas at Austin
State: 
Texas
Study End Date: 
Thu, 2016-09-15

Social Anxiety Disorder Videos

ADAA member Dr. Richard Heimberg, director of the Adult Anxiety Clinic of Temple University, explains social anxiety disorder, which affects more than 15 million Americans.

ADAA produced these videos in association with the Andrew Kukes Foundation for Social Anxiety.

NEW! Social Anxiety Disorder Videos

5/12/2014

Five new video segments to watch about understanding and overcoming social anxiety disorder.

Severe Weather: Reduce Your Anxiety

5/8/2014

Take these tips to help you take care of your  mental health and your family’s — before and after the arrival of a hurricane, tornado, or severe storm.

Treating Selective Mutism

ADAA

Steven M.S. Kurtz, PhD, ABPP

Director, Selective Mutism Program
Child Mind Institute, New York, New York

Founder of the Brave Buddies Program  

Dr. Kurtz discusses the success of tailored intensive treatment for children with selective mutism, and how kids are cured.

Listen

 

ADAA is a national nonprofit organization dedicated to the prevention, treatment, and cure of anxiety, OCD, PTSD, depression, and related disorders and to improving the lives of all people who suffer from them.

 

Privacy Policy 
© ADAA, 2010-2014